Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized trial of brivekimig in moderate to severe hidradenitis suppurativa
2025-522333-61-00Phase 2Authorised
- Sponsor
- Sanofi
- Start
- Jan 2026
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 18
01
Overview
Phase 2, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing Brivekimig arm with Placebo arm (2 arms). Primary endpoint: HiSCR75 response. Planned start Jan 2026; status: authorised.
02
Drugs
brivekimig
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2025-522333-61-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522333-61-00.